home > directory > Alfasigma


 Alfasigma is one of the leading Italian pharmaceutical company, focused on prescription drugs, self-medication and nutraceutical products. Established in 2015, after the merge of Alfa Wassermann and Sigma-Tau, today it is present with branches and distributors in around 90 countries worldwide.

In 2018 Alfasigma exceeded 1 billion Euro of turnover, half of which generated by foreign markets.

Alfasigma’s strategy is based on three guidelines which, over the years, have assured the group constant and balanced growth: Research, Technology and Internationalization.

Implementing research and technology to constantly improve its products, opening up new frontiers, extending to new markets.

During the years it has invested heavily in plant and human resources and currently has over 2,800 employees and five manufacturing plants covering almost 500,000 square metres.

As a result of the last investments, two new sterile departments for sterile powder and pre-filled syringes will become fully operational in 2020. The first, will be dedicated to the production of vials filled with sterile powders and liquids.

Attention to quality is a high priority for Alfasigma and the standards it applies comply with FDA, ANVISA, GCC, PMDA and EUGMP requirements.
email Alfasigma S.p.A. Alanno (PE), Via E.Fermi, 1 Pomezia (RM), Via Pontina, km 30,400

Member login

E-mail address:

Remember me

Industry Events

SCOPE Summit for Clinical Ops Executives

18-21 February 2020, Hyatt Regency, Orlando, Florida, US

Celebrating its 11th successful year, SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 20 different conferences, 3 plenary keynote sessions, the annual Participant Engagement Awards, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations
More info >>

News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement